AXII in the Multiple Myeloma Bone Microenvironment
多发性骨髓瘤骨微环境中的 AXII
基本信息
- 批准号:8525961
- 负责人:
- 金额:$ 7.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Adhesive interactions between myeloma (MM) cells and cells in the marrow microenvironment play an important role in tumor cell homing, lodgment and growth, as well as the bone destructive process in MM. Gene expression profiling of MM cells has shown that annexin II (AXII) is highly expressed by MM cells. We have recently cloned the AXII receptor (AXIIR) and found that AXIIR is also expressed by primary MM cells and MM cell lines. Our preliminary results suggest that AXII/AXIIR interactions play an important role in MM as well as prostate cancer bone metastasis and normal hematopoiesis. The primary goals of this application are to determine the biologic effects of AXII/AXIIR interactions between MM cells and the marrow microenvironment on MM cell growth, adhesion of MM cells to stromal cells and osteoclast (OCL) formation as well as the effects of OCL-derived AXII on MM cells and OCLs. It is our hypothesis that interactions between AXII on stromal cells and AXIIR on MM cells play an important role in lodgment of MM cells in the marrow, growth of MM cells and OCL formation. Further, OCL-derived AXII combined with growth factors released from the bone matrix by the bone destructive process stimulate the growth of MM cells to expand tumor burden in bone. To test this hypothesis: 1) we will determine if MM cells specifically bind AXII via AXIIR; 2) determine the contribution of AXII/AXIIR to adhesion and growth of MM cells in the bone marrow microenvironment, as well as the contribution of AXII/AXIIR signaling on expression of key cytokines and adhesion molecules by MM cells and stromal cells. In addition, we will assess the contribution of endogenous stromal cell AXII/AXIIR and MM cell AXII/AXIIR on the growth and adhesion of MM cells; 3) we will determine the contribution of OCL-derived AXII on the growth of MM cells; and 4) the role that AXII/AXIIR plays in MM cell homing, lodgment, and mobilization in the marrow in vivo. Results of these studies should determine the potential utility of AXII/AXIIR as a novel therapeutic target for patients with MM.
PUBLIC HEALTH RELEVANCE: The primary goals of this application are to determine the biologic effects of AXII/AXIIR interactions between myeloma (MM) cells and the marrow microenvironment on MM cell growth, adhesion of MM cells to stromal cells and osteoclast (OCL) formation as well as the effects of OCL-derived AXII on MM cells and OCLs.
描述(申请人提供):骨髓瘤(MM)细胞与骨髓微环境中的细胞之间的黏附相互作用在肿瘤细胞的归宿、生长以及MM的骨破坏过程中起着重要作用。MM细胞的基因表达谱表明MM细胞高表达膜联蛋白II(AxII)。我们最近克隆了AxII受体(AXIIR),发现AXIIR也在原代MM细胞和MM细胞系中表达。我们的初步结果表明,AxII/AXIIR相互作用在多发性骨髓瘤、前列腺癌、骨转移和正常造血中发挥着重要作用。本应用的主要目的是确定MM细胞与骨髓微环境之间的AxII/AXIIR相互作用对MM细胞生长、MM细胞与基质细胞的黏附和破骨细胞(OCL)形成的生物学影响,以及OCL来源的AxII对MM细胞和OCL的影响。我们推测,基质细胞上的AXII与MM细胞上的AXIIR的相互作用在MM细胞在骨髓中的停留、MM细胞的生长和OCL的形成中起着重要的作用。此外,OCL来源的AxII与骨破坏过程中从骨基质中释放的生长因子相结合,刺激MM细胞的生长,从而扩大骨中的肿瘤负担。为了验证这一假设:1)我们将确定MM细胞是否通过AXIIR特异性结合AxII;2)确定AxII/AXIIR在骨髓微环境中对MM细胞黏附和生长的贡献,以及AxII/AXIIR信号对MM细胞和基质细胞表达关键细胞因子和黏附分子的贡献。此外,我们将评估内源性基质细胞AxII/AXIIR和MM细胞AxII/AXIIR对MM细胞生长和黏附的贡献;3)我们将确定OCL来源的AxII对MM细胞生长的贡献;以及4)AxII/AXIIR在体内MM细胞归巢、倒伏和动员中的作用。这些研究的结果应该确定AxII/AXIIR作为MM患者新的治疗靶点的潜在用途。
公共卫生相关性:本应用的主要目标是确定AXII/AXIIR在骨髓瘤(MM)细胞和骨髓微环境之间的相互作用对MM细胞生长的生物学效应、MM细胞与基质细胞的黏附和破骨细胞(OCL)的形成,以及OCL衍生的AxII对MM细胞和OCL的影响。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Garson DAVID ROODMAN其他文献
Garson DAVID ROODMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Garson DAVID ROODMAN', 18)}}的其他基金
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease
操纵 N 端规则蛋白降解途径来构建骨并减少多发性骨髓瘤骨病中的肿瘤生长
- 批准号:
10355454 - 财政年份:2020
- 资助金额:
$ 7.16万 - 项目类别:
Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D
多发性骨髓瘤骨病对维生素 D 过敏
- 批准号:
8570680 - 财政年份:2013
- 资助金额:
$ 7.16万 - 项目类别:
Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D
多发性骨髓瘤骨病对维生素 D 过敏
- 批准号:
8704426 - 财政年份:2013
- 资助金额:
$ 7.16万 - 项目类别:
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
微环境衍生的 AXII 在骨髓瘤骨病中的作用
- 批准号:
8601259 - 财政年份:2012
- 资助金额:
$ 7.16万 - 项目类别:
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
微环境衍生的 AXII 在骨髓瘤骨病中的作用
- 批准号:
8699016 - 财政年份:2012
- 资助金额:
$ 7.16万 - 项目类别:
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
微环境衍生的 AXII 在骨髓瘤骨病中的作用
- 批准号:
8245284 - 财政年份:2012
- 资助金额:
$ 7.16万 - 项目类别:
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
微环境衍生的 AXII 在骨髓瘤骨病中的作用
- 批准号:
8793746 - 财政年份:2012
- 资助金额:
$ 7.16万 - 项目类别:
AXII in the Multiple Myeloma Bone Microenvironment
多发性骨髓瘤骨微环境中的 AXII
- 批准号:
8036058 - 财政年份:2010
- 资助金额:
$ 7.16万 - 项目类别:
AXII in the Multiple Myeloma Bone Microenvironment
多发性骨髓瘤骨微环境中的 AXII
- 批准号:
7884926 - 财政年份:2010
- 资助金额:
$ 7.16万 - 项目类别:
MVNP, p62P392L and IL-6 in the Pathogenesis of PD
MVNP、p62P392L 和 IL-6 在 PD 发病机制中的作用
- 批准号:
7809011 - 财政年份:2009
- 资助金额:
$ 7.16万 - 项目类别:
相似国自然基金
基于Multiple Collocation的北半球多源雪深数据长时序融合研究
- 批准号:42001289
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Elucidating novel epigenetic modifications implicated in multiple myeloma risk disparities
阐明与多发性骨髓瘤风险差异相关的新型表观遗传修饰
- 批准号:
10912191 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Targeting DKK1 with a DNA Vaccine to Prevent Development of Multiple Myeloma
用 DNA 疫苗靶向 DKK1 预防多发性骨髓瘤的发展
- 批准号:
10874135 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Modifiable Determinants of Disparities in Multiple Myeloma Treatment Patterns
多发性骨髓瘤治疗模式差异的可改变决定因素
- 批准号:
10578960 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Novel pro-survival mechanisms of PIM2 in multiple myeloma
PIM2 在多发性骨髓瘤中的新的促生存机制
- 批准号:
10668651 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
The genetic and epigenetic cartography of multiple myeloma
多发性骨髓瘤的遗传和表观遗传制图
- 批准号:
10648380 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma
乳腺癌、胰腺癌和多发性骨髓瘤的多模式液体活检早期评估
- 批准号:
10763336 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Differences in Tumor Biology of Multiple Myeloma in Association with African Ancestry
与非洲血统相关的多发性骨髓瘤肿瘤生物学差异
- 批准号:
10656009 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma
整合基于液体活检的表观遗传学和成像方式来评估多发性骨髓瘤的疾病反应
- 批准号:
10651370 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Engineering Biomaterials to Modulate the Bone Marrow Microenvironment in Multiple Myeloma
工程生物材料调节多发性骨髓瘤的骨髓微环境
- 批准号:
10744373 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Elucidation of pathological control mechanism of multiple myeloma by tPA/tPA receptor signaling
通过tPA/tPA受体信号传导阐明多发性骨髓瘤的病理控制机制
- 批准号:
22KF0337 - 财政年份:2023
- 资助金额:
$ 7.16万 - 项目类别:
Grant-in-Aid for JSPS Fellows














{{item.name}}会员




